Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.59 |
| ▸ | FDPS | P14324 | 2/20 | 0.56 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634044 | 0.95 | SIGMAR1 (0.61) | SIGMAR1FDPSS1PR2S1PR4S1PR1 | |
| SCHEMBL5711704 | 0.83 | CHRM2 (0.46) | S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL9038092 | 0.82 | SIGMAR1 (0.85) | SIGMAR1 | |
| SCHEMBL3115603 | 0.81 | SIGMAR1 (0.82) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL1677848 | 0.81 | SIGMAR1 (0.82) | SIGMAR1 | |
| SCHEMBL3122074 | 0.81 | SIGMAR1 (0.82) | SIGMAR1 | |
| SCHEMBL3119923 | 0.81 | SIGMAR1 (0.82) | SIGMAR1 | |
| SCHEMBL11096300 | 0.81 | SIGMAR1 (0.82) | SIGMAR1 | |
| SCHEMBL9819833 | 0.81 | SIGMAR1 (0.82) | SIGMAR1 | |
| SCHEMBL3109628 | 0.81 | SIGMAR1 (0.79) | SIGMAR1DRD2DRD4DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420008-B1 | Composition, in particular cosmetic, comprising a secondary or tertiary amine | OREAL (FR) | 2006-12-20 | — | — | EP | disclosed |
| US-20040143009-A1 | Amines, uses thereof | L'OREAL (FR) | 2004-07-22 | — | — | US | disclosed |
| US-20040105875-A1 | Composition containing a secondary or tertiary carbonyl amine, method of use thereof, compounds | L'OREAL (FR) | 2004-06-03 | — | — | US | disclosed |
| EP-1420008-A1 | Composition, in particular cosmetic, comprising a secondary or tertiary amine | L'OREAL (FR) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105875-A1 | Composition containing a secondary or tertiary carbonyl amine, method of use thereof, compounds | CUTA, COL1A1, COL14A1 | SIGMAR1 2007/4885FDPS 2375/4885S1PR2 4078/4885 |
| US-20040143009-A1 | Amines, uses thereof | COL14A1, FBL, CUTA | SIGMAR1 2275/4885FDPS 3910/4885S1PR2 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.